These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15019279)

  • 1. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
    Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
    Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
    Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
    Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
    Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen.
    Kawamoto K; Tanemura M; Nishida T; Fukuzawa M; Ito T; Matsuda H
    Transplantation; 2006 Mar; 81(5):789-96. PubMed ID: 16534484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
    Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral CTL.
    Rich RF; Cook WJ; Green WR
    Virology; 2006 Mar; 346(2):287-300. PubMed ID: 16337984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
    Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
    Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
    Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
    Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects on the inhibition of human CD8+ cytotoxic T lymphocytes-mediated killing against xenograft cells by coexpression of membrane-bound Human FasL and decoy Fas antigen.
    Tanemura M; Kawamoto K; Ito T; Uchikoshi F; Shimada K; Nishida T; Matsuda H
    Transplant Proc; 2005 Dec; 37(10):4607-9. PubMed ID: 16387181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
    Li Q; Nakadai A; Takeda K; Kawada T
    Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular and extracellular remodeling effectively prevents human CD8(+)cytotoxic T lymphocyte-mediated xenocytotoxicity by coexpression of membrane-bound human FasL and pig c-FLIP(L) in pig endothelial cells.
    Tanemura M; Saga A; Kawamoto K; Machida T; Deguchi T; Nishida T; Sawa Y; Doki Y; Mori M; Ito T
    Transplant Proc; 2009; 41(1):391-4. PubMed ID: 19249564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
    Bonardelle D; Benihoud K; Kiger N; Bobé P
    J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
    Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
    Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.
    Hallermalm K; De Geer A; Kiessling R; Levitsky V; Levitskaya J
    Cancer Res; 2004 Sep; 64(18):6775-82. PubMed ID: 15374996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
    Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.